Latest Pharmaceuticals News

Page 21 of 25
Little Green Pharma has finalized the acquisition of Health House, a key medicinal cannabis distributor, for a fraction of its previous valuation, marking a strategic move to deepen vertical integration.
Victor Sage
Victor Sage
5 Feb 2025
Neurizon Therapeutics has been granted a pivotal US patent for its lead drug candidate NUZ-001, extending protection until 2039 and enhancing its commercial and clinical positioning in neurodegenerative disease treatment.
Ada Torres
Ada Torres
5 Feb 2025
Sigma Healthcare has secured Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in reshaping Australia's pharmaceutical retail landscape.
Ada Torres
Ada Torres
4 Feb 2025
Noxopharm has successfully completed key in vitro safety tests for its SOF-SKN™ lupus drug, paving the way for the upcoming HERACLES Phase 1 clinical trial.
Ada Torres
Ada Torres
4 Feb 2025
Biotron Limited reported a robust net cash inflow of $1.095 million for the December 2024 quarter, driven largely by government grants, supporting its operational stability despite ongoing R&D expenses.
Ada Torres
Ada Torres
3 Feb 2025
Althea Group Holdings Limited has had its trading suspension lifted following a Federal Court ruling related to cleansing notice lodgement failures, marking a key regulatory milestone for the pharmaceutical company.
Ada Torres
Ada Torres
3 Feb 2025
Sigma Healthcare has received Federal Court approval for its acquisition of Chemist Warehouse, marking a pivotal step in its strategic expansion. The scheme is set to become legally effective on February 4, 2025, with implementation expected by February 12.
Ada Torres
Ada Torres
3 Feb 2025
Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.
Ada Torres
Ada Torres
31 Jan 2025
Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.
Victor Sage
Victor Sage
31 Jan 2025
HydraLyte USA has completed the divestiture of its non-US assets, wiping out debt and boosting cash reserves to US$3.2 million, while focusing its growth strategy on the US ecommerce market with a 28% quarterly revenue increase.
Ada Torres
Ada Torres
31 Jan 2025
Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.
Victor Sage
Victor Sage
31 Jan 2025
Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.
Victor Sage
Victor Sage
31 Jan 2025